PhenylpiracetamvsPiracetam

Phenylpiracetam modulates AMPA and NMDA glutamate receptors like other racetams through positive allosteric modulation. The phenyl group confers additional affinity for dopamine (DAT) and norepinephrine (NET) transporters, acting as a weak reuptake inhibitor and increasing synaptic catecholamine availability — providing stimulatory and motivational effects. It binds to α4β2 and α7 nicotinic acetylcholine receptors as a positive allosteric modulator, enhancing cholinergic transmission in the prefrontal cortex and hippocampus. The phenyl moiety improves blood-brain barrier penetration via increased lipophilicity and potentially P-glycoprotein substrate properties. Downstream effects include enhanced CREB phosphorylation and BDNF expression. The combination of glutamatergic, dopaminergic, noradrenergic, and cholinergic modulation produces synergistic cognitive enhancement.

Piracetam modulates AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) and NMDA (N-methyl-D-aspartate) glutamate receptors through positive allosteric modulation, enhancing excitatory neurotransmission without direct agonism. It increases membrane fluidity of neuronal phospholipid bilayers by reducing membrane microviscosity, which improves ion channel function and signal transmission. Piracetam enhances acetylcholine receptor density and turnover in the hippocampus, upregulating both muscarinic (M1) and nicotinic receptor expression. It potentiates the cholinergic system through increased high-affinity choline uptake. Additionally, piracetam improves cerebral blood flow via nitric oxide-dependent vasodilation and enhances oxygen utilization (glucose metabolism) in aged or hypoxic brain tissue, supporting mitochondrial function.